News

THE CHARCOT-MARIE-TOOTH ASSOCIATION LAUNCHES AMAZON STOREFRONT FEATURING ASSISTIVE GADGETS & PRODUCTS FOR THE CMT COMMUNITY The Charcot-Marie-Tooth Association (CMTA) has launched a comprehensive Amazon storefront featuring assistive gadgets and products for the CMT community. CMTA earns a commission on most of ...

With CMTA support of $302,071, an international team of researchers from the Inherited Neuropathies Consortium, led by Micheal Shy, MD, at the University of Iowa in Iowa City, IA, is studying the natural history of CMT2F to learn how this ...

Help for Today and Hope for Tomorrow: Empowering the CMT Community at the 2024 CMTA Patient & Research Summit in Denver The 2024 CMTA Patient & Research Summit in Colorado was a remarkable gathering of more than 450 attendees—both in person ...

The Charcot-Marie-Tooth Association (CMTA) continues its mission to accelerate research that impacts the lives of those living with Charcot-Marie-Tooth disease (CMT) and is excited to share progress in a CRISPR research project focused on developing gene editing strategies for CMT1A ...

CMT2S: A Potential New Treatment on the Horizon Charcot-Marie-Tooth Disease Type 2S (CMT2S) is a severe axonal type of CMT caused by certain autosomal recessive mutations of the IGHMBP2 gene. CMTA-STAR Alliance Partner Vanda Pharmaceuticals recently received USFDA approval for ...